Company intelligence / Profile preview

Carmel Diagnostics

Kiryat Tivon, Israelcarmel-diagnostics.com ↗

Ownership: Private
Development stage: Commercial

Overview

Clinical data demonstrates that the Fertissimo system can increase IVF success rates by up to 20% compared to existing gold standards. Successful clinical trials have been performed in Israel and Spain, with a new generation of the product undergoing further extensive clinical validation. Parameters measured by the analyzer correlate with embryo outcome and implantation potential.

Therapeutic areas: Women's Health
Modalities: Device (benchtop diagnostic system)Non-pharmacological therapy (diagnostic/assessment tool)
Industry: Metabolite Diagnostics

Partnerships

Merck Serono (recognized supporter/backer)

Beyond the preview

Go deeper on Carmel Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Carmel Diagnostics.

Explore the full profile